Global law firm Reed Smith announced that an M&A deal team led by partners Mark Pedretti, global chair of Reed Smith’s private equity group, and Wayne Uffleman, advised Covis Group S.à r.l. (Covis) in its sale to Azurity Pharmaceuticals, Inc. (Azurity).
Covis is a global specialty pharmaceutical company that markets therapeutic solutions in 50+ countries for patients with life-threatening conditions and chronic illnesses. Azurity is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 30+ marketed brands spanning ten dosage forms and nine key therapeutic areas.
The Reed Smith corporate team also consisted of Partners Lowell Bourgeois and Seth Merl and Associates Brent McDonough, Russell Schneider, Ashley Wong and Sarah Lee. The corporate team was supported by a number of other Reed Smith attorneys, including: a tax team led by James Tandler and Simon Kliegman; a restructuring team led by Aaron Javian, Omar Alaniz and Nicholas Vislocky; a debt team led by David Hayes, Maggie Deutsch and Cheryl Lagay; and an anti-trust team, led by Michelle Mantine and Leah Hungerman.
Goldman Sachs served as financial advisor and Eversheds Sutherland and White & Case served as legal advisors to Azurity. Guggenheim Securities served as financial advisor to Covis.
Original source can be found here.